Novel inhibitor for fibroblast growth factor receptor tyrosine kinase. 2007

Naparat Kammasud, and Chantana Boonyarat, and Satoshi Tsunoda, and Hiroaki Sakurai, and Ikuo Saiki, and David S Grierson, and Opa Vajragupta
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.

NP603, the 6-dimethoxy phenyl indolin-2-one, was designed as FGF receptor 1 inhibitor by computational study. NP603 was synthesized and found to be more active against endothelial proliferation of HUVEC after the rhFGF-2 stimulation than SU6668 with minimum effective dose of 0.4 microM but with similar potency as SU16g. NP603 inhibited the tyrosine phosphorylation in FGF receptor and the activation of extracellular signal-regulated kinase and c-Jun-N-terminal-kinase after the rhFGF-2 stimulation. The increase in activity of NP603 supports the role of Lys514 movement in ligand-receptor binding in modeling study as the movement accommodates the hydrophobic interaction at the receptor pocket leading to the enhancement of binding capacity.

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D008239 Lysine An essential amino acid. It is often added to animal feed. Enisyl,L-Lysine,Lysine Acetate,Lysine Hydrochloride,Acetate, Lysine,L Lysine
D008956 Models, Chemical Theoretical representations that simulate the behavior or activity of chemical processes or phenomena; includes the use of mathematical equations, computers, and other electronic equipment. Chemical Models,Chemical Model,Model, Chemical
D008968 Molecular Conformation The characteristic three-dimensional shape of a molecule. Molecular Configuration,3D Molecular Structure,Configuration, Molecular,Molecular Structure, Three Dimensional,Three Dimensional Molecular Structure,3D Molecular Structures,Configurations, Molecular,Conformation, Molecular,Conformations, Molecular,Molecular Configurations,Molecular Conformations,Molecular Structure, 3D,Molecular Structures, 3D,Structure, 3D Molecular,Structures, 3D Molecular
D011422 Propionates Derivatives of propionic acid. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the carboxyethane structure. Propanoate,Propanoic Acid,Propionate,Propanoates,Propanoic Acid Derivatives,Propanoic Acids,Propionic Acid Derivatives,Propionic Acids,Acid, Propanoic,Acids, Propanoic,Acids, Propionic,Derivatives, Propanoic Acid,Derivatives, Propionic Acid
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D011758 Pyrroles Azoles of one NITROGEN and two double bonds that have aromatic chemical properties. Pyrrole
D002626 Chemistry, Pharmaceutical Chemistry dealing with the composition and preparation of agents having PHARMACOLOGIC ACTIONS or diagnostic use. Medicinal Chemistry,Chemistry, Pharmaceutic,Pharmaceutic Chemistry,Pharmaceutical Chemistry,Chemistry, Medicinal
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme

Related Publications

Naparat Kammasud, and Chantana Boonyarat, and Satoshi Tsunoda, and Hiroaki Sakurai, and Ikuo Saiki, and David S Grierson, and Opa Vajragupta
March 2018, Oncotarget,
Naparat Kammasud, and Chantana Boonyarat, and Satoshi Tsunoda, and Hiroaki Sakurai, and Ikuo Saiki, and David S Grierson, and Opa Vajragupta
April 2021, Ophthalmology,
Naparat Kammasud, and Chantana Boonyarat, and Satoshi Tsunoda, and Hiroaki Sakurai, and Ikuo Saiki, and David S Grierson, and Opa Vajragupta
March 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Naparat Kammasud, and Chantana Boonyarat, and Satoshi Tsunoda, and Hiroaki Sakurai, and Ikuo Saiki, and David S Grierson, and Opa Vajragupta
January 2009, Clinical cancer research : an official journal of the American Association for Cancer Research,
Naparat Kammasud, and Chantana Boonyarat, and Satoshi Tsunoda, and Hiroaki Sakurai, and Ikuo Saiki, and David S Grierson, and Opa Vajragupta
September 1990, The Journal of biological chemistry,
Naparat Kammasud, and Chantana Boonyarat, and Satoshi Tsunoda, and Hiroaki Sakurai, and Ikuo Saiki, and David S Grierson, and Opa Vajragupta
December 2002, Microcirculation (New York, N.Y. : 1994),
Naparat Kammasud, and Chantana Boonyarat, and Satoshi Tsunoda, and Hiroaki Sakurai, and Ikuo Saiki, and David S Grierson, and Opa Vajragupta
April 2012, Cancer research,
Naparat Kammasud, and Chantana Boonyarat, and Satoshi Tsunoda, and Hiroaki Sakurai, and Ikuo Saiki, and David S Grierson, and Opa Vajragupta
July 2004, The Journal of biological chemistry,
Naparat Kammasud, and Chantana Boonyarat, and Satoshi Tsunoda, and Hiroaki Sakurai, and Ikuo Saiki, and David S Grierson, and Opa Vajragupta
August 1994, Science (New York, N.Y.),
Naparat Kammasud, and Chantana Boonyarat, and Satoshi Tsunoda, and Hiroaki Sakurai, and Ikuo Saiki, and David S Grierson, and Opa Vajragupta
January 2004, Breast cancer research and treatment,
Copied contents to your clipboard!